Health Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma James Pereira Jan 4, 2023 A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in… Read More...
Health New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC James Pereira Aug 10, 2022 VIENNA -- Longer follow-up in the so-called IMpower010 trial… Read More...
Health Atezolizumab Improves Survival Rate in Bladder Cancer Patients James Pereira Jul 4, 2022 Results showed no significant difference in overall survival between the two groups in the intention-to-treat… Read More...
Health Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in… James Pereira May 9, 2022 VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily… Read More...
Health Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in… James Pereira Feb 11, 2022 Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial for the treatment of advanced… Read More...
Health Pre-Op Atezolizumab Promising in Muscle-Invasive Bladder Cancer James Pereira Feb 8, 2022 The use of a checkpoint… Read More...
Health Disease Control With Cabozantinib Plus Atezolizumab in CRPC James Pereira Oct 4, 2021 For previously treated patients with… Read More...
Health Atezolizumab Regimen Safe in Resectable Mesothelioma James Pereira Oct 1, 2021 Use of atezolizumab (Tecentriq) as part… Read More...
Health Genentech Pulls Atezolizumab’s Breast Cancer Approval James Pereira Aug 28, 2021 Genentech announced that… Read More...
Health Add-On PD-L1 Inhibitor Promising in Muscle-Invasive Bladder Cancer James Pereira Jul 9, 2021 Adding the PD-L1 inhibitor atezolizumab… Read More...